Third quarter: Orthopaedics strong but CRM & DESs (drug-eluting stents) still suffering
This article was originally published in Clinica
Executive Summary
Abbott Laboratories' reported medical products sales rose by 20% in the third quarter, boosted by the acquisition of Guidant's vascular products, which helped Abbott Vascular achieve sales of $351m. Diagnostics revenues were up 8.6% at $1bn, with the US business providing 9.9% growth to $337m, driven by the launch of the Prism blood screening system and double-digit growth in molecular and point of care testing. Diabetes care revenues increased by 4.9% to $283m, with growth coming from the non-US markets and US sales virtually flat at $133m.